Reviva’s antipsychotic shows promise against schizophrenia symptoms in year-long study

In the wake of the approval Bristol Myers Squibb’s Cobenfy, it seems that news has ramped up in the schizophrenia space. The latest contender is Reviva Pharmaceuticals’ brilaroxazine, which reduced schizophrenia symptoms over a year in a phase 3 trial.